Merck, Eisai liver cancer trial misses endpoints

Thursday 4 August 2022

United States

A Phase 3 trial of a combination therapy intended to improve the standard of care for the most common type of liver cancer failed to meet its dual primary endpoints, Merck & Co Inc and Eisai Co Ltd announced on 3 August. The trial was investigating Keytruda (pembrolizumab) and Lenvima (lenvatinib) as a first-line treatment for patients with unresectable hepatocellular carcinoma versus Lenvima alone.